Affymax, Inc. is a biopharmaceutical company previously committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision was to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers before a nationwide voluntary recall of OMONTYS® (peginesatide) Injection in February 2013. In March 2013 Affymax commenced a review of strategic alternatives.
|Type||Public / Private|
Top 5 Recent Tweets
|May 09, 2020||mhoran1158||John D. Diekman. (Apr. 01, 1991). Affymax Technologies N.V. letter from John D. Diekman to Sydney Brenner re. inves… https://t.co/9wEpYchbRC|